Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

A Validation Study to Determine Concordance of Liquid Biopsy and Breast Cancer Diagnosis

NCT06336928 · View on ClinicalTrials.gov ↗

Study Summary

This study evaluates whether a special type of blood analysis, called liquid biopsy (LBx), correlates with mammography results and/or diagnosis of breast cancer.

Conditions Studied

Interventions

  • OTHER Non-Interventional Study

Study Locations (4)

California

  • Keck Medicine of USC Koreatown — Los Angeles
  • Los Angeles General Medical Center — Los Angeles
  • USC / Norris Comprehensive Cancer Center — Los Angeles
  • USC Norris Oncology/Hematology-Newport Beach — Newport Beach

Trial Details

FieldValue
Enrollment Target 490 participants
Start Date 2024-06-07
Est. Completion 2030-06-07

Sponsor

University of Southern California

412 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06336928

The ClinicalTrials.gov registry entry for NCT06336928 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 490 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Southern California, which has 412 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Breast Carcinoma appearing as the primary indexed condition, and to 1 intervention — of which Non-Interventional Study is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06336928 reports 4 study locations spanning 1 distinct geographic area — top geographies include California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06336928 about?

NCT06336928 is a clinical study titled "A Validation Study to Determine Concordance of Liquid Biopsy and Breast Cancer Diagnosis". This study evaluates whether a special type of blood analysis, called liquid biopsy (LBx), correlates with mammography results and/or diagnosis of breast cancer.

What is the current status of trial NCT06336928?

This trial is currently recruiting. The enrollment target is 490 participants. The study started on 2024-06-07. Estimated completion is 2030-06-07.

What conditions does trial NCT06336928 study?

This clinical trial studies the following conditions: Breast Carcinoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06336928?

The interventions under investigation include: Non-Interventional Study (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06336928?

This trial is sponsored by University of Southern California, which has 412 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06336928 being conducted?

This trial has 4 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial